Neurodegenerative Diseases Articles & Analysis
132 news found
These include E3 ligase ligands such as CRBN and VHL, and linkers which act as a mediator between target proteins and ligases to broaden the therapeutic options (especially in the treatment of cancer and neurodegenerative diseases). Nucleosides, the building blocks of nucleic acids, aren’t only simple building blocks for RNA and DNA. ...
This comprehensive collection provides researchers with a unique resource to study various neurological conditions and accelerate their investigations into neurological diseases and disorders. CD Bioscience has been developing imaging technologies for many years and uses high content imaging, nanoparticle imaging, imaging flow cytometry, time-lapse imaging and other technologies ...
Neuroscience: The exploration of the roles played by 5mC and 5hmC in neurodevelopment and neurodegenerative diseases holds the promise of revealing new therapeutic targets. ...
In the pursuit of advancing disease research and its treatment, animal cognitive behavior is studied in a wide range of animal species. ...
Emotion-related animal behavior tests aim to provide a good research tool for the study of emotion-associated diseases. Anxiety and depression affect millions of individuals worldwide, leading to a significant burden on public health and impacting overall quality of life. Depression is commonly seen in neurodegenerative and neurodevelopmental ...
At the end of the 19th century, the German scientist Paul Ehrlich began to realize that certain chemicals could have highly specific effects on certain diseases. He began to write about the possibility that a drug could act like a magische kugel—magic bullet—that killed only the organism causing disease, and nothing else. Today, ...
A five-year action plan developed to meet requirements under Section 4 of the Accelerating Access to Critical Therapies for ALS Act. ...
Anle138b targets pathological alpha-synuclein oligomers and is being evaluated in patients with neurodegenerative diseases for potential disease modification. Under the terms of the agreement and pending regulatory clearance, Teva will receive an exclusive global license to develop, manufacture and commercialize anle138b and sery433. ...
Phase 1 trial of tau-targeting lead program planned to begin in 3Q22 Funding will also support the characterization of the Company’s second-generation assets Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, announced that the ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced that the U.S. ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for Alzheimer’s and rare neurodegenerative diseases, announced that the Company presented data from a therapeutic study in an animal model of its lead product candidate OLX-07010 at the 14th Annual Clinical Trials on Alzheimer's ...
BlueRock, a pioneer in stem cell engineered cell therapy, is advancing a growing pipeline of innovative therapies for treating patients with neurological, immunological, cardiovascular and ophthalmic diseases. Its most advanced program BRT-DA01 is being developed for the treatment of Parkinson’s disease, a progressive neurodegenerative ...
ByBayer AG
The technology is designed to advance treatments for neurodegenerative diseases, including therapies with complex molecules such as monoclonal antibodies and larger peptides, by allowing medication to cross the blood-brain barrier and access the most penetrable part of the blood-brain barrier at the top of the nasal cavity. Led by a team of experienced ...
Oligomerix, Inc., a privately held company pioneering the development of small molecule therapeutics targeting tau for rare neurodegenerative and Alzheimer’s diseases, today announced the presentation of IND-enabling preclinical data on its lead product candidate OLX-07010 at the annual Clinical Trials on Alzheimer's Disease (CTAD) and ...
“Our primary goal is to deliver the AAV resources, scale, technology, and expertise for our partners to help patients living with diseases like ALS with no known cure.” ALS is a rare neurological disease with significant socioeconomic impact, whose patients are desperate for novel, safe and effective therapies. ...
InMed will be conducting studies using in vivo models in neurodegenerative disease to select the most appropriate candidate for clinical studies. ...
The company's Opal Computational Platform™ is an integrated set of capabilities designed to transform data into valuable insights that may accelerate discoveries and enable Valo to advance a robust pipeline of programs across cardiovascular metabolic renal, oncology, and neurodegenerative disease. Founded by Flagship Pioneering and headquartered in Boston, ...
The role of the immune system and inflammation in Alzheimer’s disease has been broadly known for years but it is becoming increasingly clear that effective management of AD may require anti-inflammatory strategies. ...
Not only will the new test be important in helping physicians predict the likely course of disease — for example, fast versus slow progression — in individuals with ALS, but it will help inform clinical trial enrollment and potentially accelerate the pace of drug development for ALS. ...
BynVector
Krabbe disease affects infants with an incidence rate of 1-2.5 in 100,000 and leads to premature death, often by 2 years of age. ...